Form 4: Akero Therapeutics CEO Andrew Cheng Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Akero Therapeutics' CEO, Andrew Cheng, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Andrew Cheng, CEO of Akero Therapeutics, executed stock options to acquire common stock at a price of $21.10 per share.
- Simultaneously, Cheng sold portions of these shares on October 16, 17, and 18, 2024, at weighted average prices ranging from approximately $31.12 to $32.12.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 25, 2023.
- Following these transactions, Cheng directly owns 605,417 shares of Akero Therapeutics common stock.
- He also holds options to purchase 93,709 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. No indication of positive or negative company performance is implied.
Positives
- The use of a pre-arranged 10b5-1 trading plan suggests the transactions were planned and not based on insider information.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans is a standard practice to avoid insider trading concerns.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature mitigates concerns.
Key Dates
| Date | Description |
|---|---|
| May 25, 2023 | Date of Rule 10b5-1 trading plan adoption |
| 10/16/2024 | Date of first reported transaction (option exercise and share sale) |
| 10/17/2024 | Date of second reported transaction (option exercise and share sale) |
| 10/18/2024 | Date of third reported transaction (option exercise and share sale) |
| 12/07/2031 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.